Tetracycline, erythromycin, and clindamycin resistance among Streptococcus pyogenes isolates: a retrospective study from a tertiary care hospital in Türkiye (2011–2025)
This study aimed to evaluate temporal trends in resistance to clindamycin, erythromycin, and tetracycline among Streptococcus pyogenes (Group A Streptococcus [GAS]) isolates and to compare antimicrobial resistance patterns before, during, and after the COVID-19 pandemic. This retrospective study included patients younger than 18 years of age with S. pyogenes samples isolated between January 2011 and January 2025. The study was conducted at the Faculty of Medicine Hospital of *Çukurova***** University, a tertiary care center in Türkiye. Isolates recovered from blood, throat swabs, cerebrospinal fluid, skin and soft tissue swabs, peritoneal fluid, tracheal aspirates, nasal swabs, eye swabs, and ear discharge specimens were analyzed. The study period was categorized as the pre-COVID-19 period (2011–2019), the COVID-19 period (2020–2022), and the post-COVID-19 period (2023–2024). A total of 339 S. pyogenes isolates were identified. Most of them were recovered from skin and soft tissue specimens ( n = 152, 44.8%). Overall resistance rates were 37.7% for tetracycline, 14.1% for erythromycin, and 6.8% for clindamycin. Consistent with previous reports, tetracycline resistance remained high throughout the study period. Resistance increased significantly during the COVID-19 period and, although it declined thereafter, remained substantially elevated during the post-pandemic period (Pre-COVID:30.6%, COVID Period: 55.9%, Post-COVID: 32.4%) ( p = 0.004). Among the 57 throat isolates tested for all three antibiotics, only one isolate (1.8%) exhibited concurrent resistance to clindamycin, erythromycin, and tetracycline. This isolate was identified during the post-COVID-19 period. Adjunctive clindamycin is recommended for severe invasive GAS infections because of its toxin-suppressing effect, while macrolides are used in patients with β-lactam allergy. In our study, no statistically significant differences in clindamycin or macrolide resistance rates were observed across the study periods. Nevertheless, given the clinical importance of these antibiotics, continued surveillance of local antimicrobial resistance patterns remains essential to guide empirical treatment decisions and support antimicrobial stewardship. Not applicaple.
Authors
- Asena Ünal (ORCID: https://orcid.org/0000-0003-2233-0513)
- Filiz Kibar (ORCID: https://orcid.org/0000-0003-2983-2399)
- Derya Alabaz (ORCID: https://orcid.org/0000-0003-4809-2883)
- Özlem Özgür Gündeşli̇oğlu (ORCID: https://orcid.org/0000-0003-2202-7645)
- Ümmühan Çay (ORCID: https://orcid.org/0000-0001-5803-878X)
- Göksu Başargan (ORCID: https://orcid.org/0000-0002-6992-9593)
- Hatice Gümüş (ORCID: https://orcid.org/0000-0001-9071-9606)
- Fatma Tuğba Çetin (ORCID: https://orcid.org/0000-0002-0471-8939)
- Gökçe Oğuz (ORCID: https://orcid.org/0000-0001-7504-345X)
- Kayra Akın (ORCID: https://orcid.org/0009-0007-8906-1553)
Institutions
- Cukurova University (TR)
Publication Details
- Journal
- BMC Infectious Diseases
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1186/s12879-026-14885-0
- Primary Topic
- Streptococcal Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00